mBIOTA Elemental Diet Named to TIME 2025 Best Inventions List
Novel palatable elemental diet recognized among the world’s most groundbreaking inventions for achievements in redefining the management of gastrointestinal conditions
Santa Monica, October 9, 2025 – mBIOTA Labs, a medical food company revolutionizing the field of therapeutic nutrition, today announced that its flagship product, mBIOTA Elemental™ Diet, was named to the TIME 2025 Best Inventions List for its novel solution for chronic GI disorders. mBIOTA Elemental™ Diet is the first clinically proven and highly palatable medical food designed for the nutritional management of gastrointestinal (GI) dysfunction, including small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth
(IMO), irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD), and eosinophilic esophagitis (EoE). The science-backed formula, developed in partnership with leading gastroenterologist researchers and food scientists, delivers complete nutrition while providing relief and remission for patients suffering through painful GI disorders.
“mBIOTA Labs is beyond thrilled that our first product is included in TIME’s list of Best Inventions and has proven itself as an incredibly impactful medical solution both clinically and in the real world,” said Krystyna Houser, founder of mBIOTA Labs. “This honor is a testament to our rigorous, science-based work and advocacy for a better experience for the millions of individuals who currently struggle with GI symptoms without a truly viable solution. We look forward to continuing this momentum as we grow our clinical vision and footprint across new use cases for palatable elemental diets.”
With over 62 million people diagnosed with GI disorders annually, most hospital systems recommend antibiotics or biologics as the course of action for those enduring severe GI symptoms. Yet today, many prefer to avoid harsh medications or find antibiotics ineffective. mBIOTA Elemental Diet launched in 2024, reintroducing elemental diets to GI management strategies through a novel palatable formula that drastically increased patient compliance and bacterial eradication. The solution delivers a nutrition-based and clinically proven option that physicians trust directly to consumers. To date, the company is working with 2,000+ providers and has supported several thousands of patients across the U.S. and 39 countries internationally.
Clinical research findings about the product’s efficacy were published in the Clinical Gastroenterology and Hepatology journal in April 2025, cited in more than four papers within just six months. Clinical findings were also presented at the November 2024 Federation of Neurogastroenterology & Motility Meeting, a distinguished platform for clinicians, researchers, and professionals from all over the world to exchange knowledge and advancements in the field of neurogastroenterology and motility. The trial was additionally awarded the prestigious Presidential Poster Award as well as the Outstanding Research Award in the Small Intestine Category at the American College of Gastroenterology (ACG) Research Conference in October 2024, and earned a feature oral presentation at Digestive Disease Week (DDW) 2025. Clinical findings of mBIOTA Elemental will be featured in seven different abstracts at the next ACG Research Conference in October 2025, one of which also received a Presidential Poster Award.
See the full TIME 2025 Best Inventions list here: time.com/collections/best-inventions-2025/
About mBIOTA Labs
mBIOTA Labs empowers individuals with evidence-based nutrition solutions that enhance quality of life. Trusted by the medical community, mBIOTA Labs harnesses proprietary Amino Taste Modification Technology (ATMT) to create science-backed medical foods designed to support individuals with a wide range of digestive issues. mBIOTA's award-winning, clinically proven, palatable elemental diet, mBIOTA Elemental™, revolutionizes medical nutrition for the dietary management of GI dysfunction, including small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD) such as Crohn’s disease and colitis, eosinophilic esophagitis (EoE), and other conditions. mBIOTA is actively investigating and researching expanded applications of the elemental diet to aid and provide solutions to more patients. Learn more about mBIOTA Labs and published research supporting mBIOTA Elemental Diet by visiting www.mBIOTA.com.
